Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Inclusion Criteria: * Documented informed consent of the participant * Agreement for confirmatory pre-treatment tumor biopsy * If a patient does not have an easily accessible lymph node to biopsy without excessive risk in the opinion of the investigator, archival biopsy material reviewed by a hematopathologist at the enrolling site for study eligibility and baseline correlatives may be acceptable with approval from the Study principal investigator (PI) * Age: \>= 18 years * Eastern cooperative oncology group (ECOG) \<= 2 * Histologically confirmed Richter's Transformation (RT) * Relapsed / refractory following \>=2 prior lines of systemic therapy; OR refractory to first-line chemoimmunotherapy; OR relapsed within 12 months of first line chemoimmunotherapy; OR relapsed after first line of chemoimmunotherapy and not eligible for hematopoietic stem cell transplantation due to comorbidities or age * Eligible to receive liso-cel and ibrutinib per package inserts * Fully recovered from the acute toxic effects (except alopecia) to \<= Grade 1 to prior anti-cancer therapy * Absolute neutrophil count (ANC) \>= 750/mm\^3 unless there is bone marrow involvement * Platelets \>= 75,000/mm\^3 unless there is bone marrow involvement * Total bilirubin =\< 1.5 X ULN (unless has Gilbert's disease) * Aspartate aminotransferase (AST) =\< 2.5 x ULN * Alanine aminotransferase (ALT) =\< 2.5 x ULN * Creatinine clearance of \>= 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula * Int…